| AXG 0.04 -25.65% | SHFS 0.1158 23.19% | DVLT 0.067 -49.55% | XXII 0.1048 18.55% | NEXR 0.5454 21.77% | SOFI 16.4 13.42% | WFF 0.0601 -33.07% | NU 12.4 -1.51% | NVD 3.93 -1.50% | SPCX 148.58 1.14% | SOXL 101.08 11.69% | EWZ 34.3 0.45% | INTC 93.74 3.61% | NVDA 217.94 0.90% | BBD 2.91 -0.51% | SOXS 42.5 -11.42% | GPUS 0.2126 19.10% | JBLU 2.82 18.99% | GRAB 2.72 0.37% | NOK 8.89 3.30% | VALE 11.84 -1.33% | SNTI 0.1867 6.62% | AAL 12.61 3.36% | HYG 77.6 0.52% | BITO 10.79 1.27% | CRWV 59.57 7.94% | TSLL 11.63 8.09% | RCT 0.0656 -20.68% | META 620.19 -1.64% | TQQQ 71.04 3.81% | QID 13.86 -2.53% | STLA 4.14 1.47% | NFLX 62.52 -2.16% | TSLG 5.82 8.18% | ONDS 6.65 7.95% | BA 168.18 -10.69% | IREN 27.44 7.90% | T 20.94 0.46% | BRAI 3.31 56.13% | PLUG 1.4 2.19% | TSLA 407.46 4.04% | CIFR 8.48 9.99% | RIG 6.46 -1.07% | F 11.71 1.12% | RWM 14.34 -1.10% | XP 15.96 1.62% | KORU 11.86 8.91% | AAPL 347.1 0.93% | ITUB 7.67 -0.39% | SNAP 6.06 -4.42%

Incyte Highlights Promising Early Data for '890 and '734 in GI Cancers

Incyte NASDAQ: INCY presented updated clinical data and development plans for two experimental solid-tumor programs at ESMO in Madrid: INCA33890, a…

TC Trade Conquest Newsroom October 26, 2026 ·1 min read

Incyte Highlights Promising Early Data for '890 and '734 in GI Cancers

Incyte NASDAQ: INCY presented updated clinical data and development plans for two experimental solid-tumor programs at ESMO in Madrid: INCA33890, a TGFβR2-by-PD-1 bispecific antibody known as “'890,” and INCB161734, a KRAS G12D-targeted small molecule known as “'734.”

See the latest quote, chart and news for INCY.

Read the full story at marketbeat.com ↗

Want trade ideas like this in real time? Subscribe to Trade Conquest.

More news